GeneDx Holdings(WGS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

WGS GeneDx Holdings

Trading 01-15 11:41:19 EST

108.09

+3.53

+3.38%

High109.43	Low103.01	Vol199.60K
Open105.89	D1 Closing104.56	Amplitude6.14%
Mkt Cap3.12B	Tradable Cap2.16B	Total Shares28.90M
T/O21.17M	T/O Rate1.00%	Tradable Shares19.94M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"WGS","market":"US","secType":"STK","nameCN":"GeneDx Holdings","latestPrice":108.09,"timestamp":1768495273879,"preClose":104.56,"halted":0,"volume":199597,"delay":0,"floatShares":19944938,"shares":28904590,"eps":0.073539,"marketStatus":"Trading","change":3.53,"latestTime":"01-15 11:41:19 EST","open":105.89,"high":109.43,"low":103.01,"amount":21172229.81933,"amplitude":0.0614,"askPrice":108.7,"askSize":35,"bidPrice":108.09,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.073539,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1768510800000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":104.56,"preHourTrading":{"tag":"盘前","latestPrice":108.49,"preClose":104.56,"latestTime":"09:18 EST","volume":654,"amount":69717.73416,"timestamp":1768486733054},"postHourTrading":{"tag":"盘后","latestPrice":105,"preClose":104.56,"latestTime":"19:28 EST","volume":2243,"amount":236108.4799,"timestamp":1768436904560},"volumeRatio":0.650502,"impliedVol":0.565,"impliedVolPercentile":0.012},"requestUrl":"/m/hq/s/WGS/wiki","defaultTab":"wiki","newsList":[{"id":"1176591322","title":"Stock Track | GeneDx Holdings Plummets 5.07% Intraday Amid Mixed Analyst Opinions","url":"https://stock-news.laohu8.com/highlight/detail?id=1176591322","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176591322?lang=en_us&edition=fundamental","pubTime":"2026-01-13 23:10","pubTimestamp":1768317017,"startTime":"0","endTime":"0","summary":"GeneDx Holdings (WGS) saw its stock price drop sharply by 5.07% during intraday trading on Tuesday, reflecting investor concerns following mixed analyst opinions on the company.The healthcare sector,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["WGS"],"gpt_icon":0},{"id":"2602954650","title":"GeneDx Shares Down 2.5% After Announcing Preliminary Q4 Results, 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2602954650","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602954650?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:31","pubTimestamp":1768228298,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0DR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["WGS","BK4196"],"gpt_icon":0},{"id":"2602548585","title":"GeneDx Reports Preliminary Q4 Revenue; Issues 2026 Revenue Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2602548585","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602548585?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:22","pubTimestamp":1768224171,"startTime":"0","endTime":"0","summary":"GeneDx  said Monday it expects fiscal Q4 revenue of $121 million.Analysts polled by FactSet expect $120.4 million.For full year 2025, the company said it expects total revenue of $427 million.Analysts surveyed by FactSet expect $427 million.The company also said it expects 2026 revenue of between $540 million and $555 million.Analysts polled by FactSet expect $529.2 million.GeneDx said it will report its Q4 results on Feb. 23 before the US market opens.Shares of the company were down 8.4% in recent Monday premarket activity.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["WGS","BK4196"],"gpt_icon":0},{"id":"2602517158","title":"Genedx Holdings Corp. unveils presentation highlighting advances in rare disease diagnosis and genomics-driven healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2602517158","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602517158?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:52","pubTimestamp":1768222322,"startTime":"0","endTime":"0","summary":"GeneDx Holdings Corp. presented at the J.P. Morgan 2026 Healthcare Conference, providing an overview of its current initiatives and advancements in rare disease diagnosis. The company highlighted its GeneDx Infinity platform, which comprises approximately one million exomes and genomes and over 2.5 million genetic tests, forming what it describes as the largest and most diverse rare disease dataset. The presentation detailed the use of proprietary AI models and algorithms to improve diagnostic accuracy, speed, and efficiency. GeneDx reported that more than 60% of its data includes parental information and over 50% represents individuals of non-European descent, supporting efforts to enhance diagnostic capabilities across populations. The company also outlined its collaborations with health systems, biopharma partners, advocacy groups, and policymakers to support patient care, accelerate drug discovery, and promote equitable access to genomic insights. You can access the full presentati","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL9MFHh4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2023250504.SGD","LU0238689110.USD","LU0345770993.USD","LU1974910355.USD","LU2552382215.SGD","LU1366192091.USD","LU0106831901.USD","LU0787776722.HKD","LU2505996681.GBP","LU1917777945.USD","LU2746668974.SGD","WGS","LU0211326755.USD","LU0345769128.USD","IE00BN8TJ469.HKD","LU0256863811.USD","LU2462157665.USD","IE00BKVL7J92.USD","LU0211327993.USD","LU0976567544.SGD","LU0203347892.USD","IE00B775SV38.USD","LU1280957306.USD","LU1496350171.SGD","IE00BJLML261.HKD","LU2106854487.HKD","LU0310799852.SGD","LU2237443382.USD","LU0820561818.USD","LU0070302665.USD","LU2456880835.USD","IE00BLSP4452.SGD","LU1261432733.SGD","IE000M9KFDE8.USD","LU0265550946.USD","IE0034235303.USD","LU1116320737.USD","LU0251132253.USD","LU1032466523.USD","LU0882574139.USD","LU1496350502.SGD","LU2023250330.USD","LU0640476718.USD","LU1244550221.USD","LU0942090050.USD","LU1244550577.SGD","LU2505996509.AUD","IE00BFXG1179.USD","IE00BLSP4239.USD","LU0417517546.SGD"],"gpt_icon":0},{"id":"2602517205","title":"GeneDx reports preliminary Q4 revenue $121M, consensus $120.49M","url":"https://stock-news.laohu8.com/highlight/detail?id=2602517205","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602517205?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:50","pubTimestamp":1768222220,"startTime":"0","endTime":"0","summary":"Reports preliminary FY25 revenue $427M, consensus $427.04M. “In 2025, GeneDx (WGS) continued its journey of transforming the standard of pediatric ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/genedx-reports-preliminary-q4-revenue-121m-consensus-120-49m-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/genedx-reports-preliminary-q4-revenue-121m-consensus-120-49m-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4196","WGS"],"gpt_icon":0},{"id":"2602249512","title":"GeneDx Projects 2026 Revenue of Up to $555 Million with Strong Exome and Genome Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2602249512","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602249512?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:31","pubTimestamp":1768221093,"startTime":"0","endTime":"0","summary":"GeneDx Holdings Corp. has announced its preliminary financial results for 2025 and shared its outlook for 2026. For the full year 2025, the company expects revenues of approximately $427 million, representing a 41% increase year-over-year. Exome and genome revenue is projected to grow by 54% for the year, or 58% when excluding a one-time benefit in 2024. Exome and genome volume growth is expected to exceed 30% for 2025, with the fourth quarter accelerating to 34.3%. The adjusted gross margin for both the full year and fourth quarter of 2025 is anticipated to be 71%. Looking ahead to 2026, GeneDx forecasts revenues between $540 million and $555 million, with exome and genome revenue and volume expected to grow by 33% to 35%. The company also expects an adjusted gross margin of at least 70% and positive adjusted net income for the year.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL3zSYTM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","WGS"],"gpt_icon":0},{"id":"2602512118","title":"GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2602512118","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602512118?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:30","pubTimestamp":1768221002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA83VNPF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["WGS","BK4196"],"gpt_icon":0},{"id":"2602251229","title":"GeneDx Holdings Corp - Expects 2025 Revenues of $427 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2602251229","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602251229?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:30","pubTimestamp":1768221002,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA83VNPF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4196","WGS"],"gpt_icon":0},{"id":"2602160512","title":"GeneDx Q4 Revenue USD 121 Million VS. Ibes Estimate USD 116.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2602160512","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602160512?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:30","pubTimestamp":1768221001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nPLXA04D81:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["WGS","BK4196"],"gpt_icon":0},{"id":"2602955318","title":"Fact Check: Superflu Is Not More Dangerous Than Covid-19","url":"https://stock-news.laohu8.com/highlight/detail?id=2602955318","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602955318?lang=en_us&edition=fundamental","pubTime":"2026-01-11 15:14","pubTimestamp":1768115683,"startTime":"0","endTime":"0","summary":"TEMPO.CO, Jakarta - A post claiming that the Superflu virus, or influenza A9H2 subclade K virus, was more severe than Covid-19 circulated on TikTok [archive] and Facebook on January 2, 2025.The post showed an image of two people wearing white hazmat suits. The post's caption read,“Baru sehari 2026, virus Super Flu sudah masuk Indonesia, lebih parah daripada Covid-19”.As of this writing, the content has been viewed 590,000 times, liked 2,509 times, and commented on by 1,422 users. But is it true that the Superflu virus is more severe and dangerous than the Covid-19 virus?","market":"sg","thumbnail":"https://statik.tempo.co/data/2026/01/09/id_1452424/1452424_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2026/01/09/id_1452424/1452424_720.jpg"],"rights":{"source":"tempo_highlight","url":"https://en.tempo.co/read/2079615/fact-check-superflu-is-not-more-dangerous-than-covid-19","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/2079615/fact-check-superflu-is-not-more-dangerous-than-covid-19","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["WGS","BK4196"],"gpt_icon":0},{"id":"2602582514","title":"Researcher: Super Flu Cases in Indonesia Could Be Fatal for Vulnerable Groups","url":"https://stock-news.laohu8.com/highlight/detail?id=2602582514","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602582514?lang=en_us&edition=fundamental","pubTime":"2026-01-10 16:00","pubTimestamp":1768032000,"startTime":"0","endTime":"0","summary":"TEMPO.CO, Jakarta- A researcher from Gadjah Mada University (UGM) has warned that so-called “super flu” cases in Indonesia need close monitoring, even though the virus has not shown signs of increased","market":"sh","thumbnail":"https://statik.tempo.co/data/2026/01/08/id_1452122/1452122_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2026/01/08/id_1452122/1452122_720.jpg"],"rights":{"source":"tempo_highlight","url":"https://en.tempo.co/read/2079434/researcher-super-flu-cases-in-indonesia-could-be-fatal-for-vulnerable-groups","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/2079434/researcher-super-flu-cases-in-indonesia-could-be-fatal-for-vulnerable-groups","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["BK4196","WGS"],"gpt_icon":0},{"id":"2601393651","title":"Analysts Offer Insights on Healthcare Companies: Quanterix (QTRX), Indivior (INDV) and GeneDx Holdings (WGS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2601393651","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601393651?lang=en_us&edition=fundamental","pubTime":"2026-01-08 22:50","pubTimestamp":1767883840,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Quanterix (QTRX – Research Report), Indivior (INDV – Research Rep...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-quanterix-qtrx-indivior-indv-and-genedx-holdings-wgs-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-quanterix-qtrx-indivior-indv-and-genedx-holdings-wgs-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4121","BK4581","BK4585","HCSG","LU0029874061.USD","XLV","BK4137","QTRX","INDV","XBI","BK4588","LABU","LU0128526141.USD","WGS","BK4196"],"gpt_icon":0},{"id":"2601362943","title":"GeneDx and Komodo Health Partner to Build Comprehensive Rare Disease Dataset","url":"https://stock-news.laohu8.com/highlight/detail?id=2601362943","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601362943?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:30","pubTimestamp":1767879051,"startTime":"0","endTime":"0","summary":"Genedx Holdings Corp. has announced a strategic partnership with Komodo Health to build the world’s most comprehensive longitudinal rare disease dataset. By integrating GeneDx’s genomic and phenotypic data with real-world patient insights from Komodo’s Healthcare Map, the collaboration aims to provide unprecedented visibility into rare disease diagnosis, management, and treatment across the patient journey. This partnership is expected to accelerate research, support biopharma innovation, and improve patient outcomes, while maintaining strict standards for privacy and data security.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genedx Holdings Corp. published the original content used to generate this news brief via Business Wire  on ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL296g6R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","WGS"],"gpt_icon":0},{"id":"2601805463","title":"GeneDx Launches GenomeDx Prenatal Whole Genome Sequencing for Prenatal Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2601805463","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601805463?lang=en_us&edition=fundamental","pubTime":"2026-01-07 21:30","pubTimestamp":1767792657,"startTime":"0","endTime":"0","summary":"GeneDx Holdings Corp. has announced the launch of GenomeDx Prenatal, a new whole genome sequencing  service designed for prenatal care. This expansion brings industry-leading genomic diagnostics to pregnancies with fetal anomalies identified via ultrasound, enabling faster and more comprehensive diagnosis. GenomeDx Prenatal offers rapid turnaround, robust variant detection, and supports families with postnatal and lifetime reanalysis options. The new service will be available for clinicians to order beginning in February 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genedx Holdings Corp. published the original content used to generate this news brief via Business Wire  on January 07, 2026, and is solely responsible for the infor","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL5bK6Ns:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WGS","BK4196"],"gpt_icon":0},{"id":"2601806278","title":"Super Flu Virus Is Weak Variant, Says Health Minister","url":"https://stock-news.laohu8.com/highlight/detail?id=2601806278","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601806278?lang=en_us&edition=fundamental","pubTime":"2026-01-07 19:46","pubTimestamp":1767786360,"startTime":"0","endTime":"0","summary":"TEMPO.CO,Jakarta-Health Minister Budi Gunadi Sadikin stated that the \"super flu\" virus is a weak variant and does not cause death. He mentioned that a strong immune system, sufficient nutrition, and enough rest effectively fend off the virus.\"If our immune system is strong, with sufficient food, enough sleep, and adequate exercise, God willing, if a weak virus like this super flu enters, we can recover,\" Budi said during a press conference at the Graha BNPB Office, Jakarta, Wednesday, Jan. 7, 2026.The former Bank Mandiri President Director explained that the super flu is not a new disease. The virus is a common influenza variant caused by the A H3N2 strain, which later produced a new variant known as subclade K.","market":"fut","thumbnail":"https://statik.tempo.co/data/2026/01/07/id_1451966/1451966_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2026/01/07/id_1451966/1451966_720.jpg"],"rights":{"source":"tempo_highlight","url":"https://en.tempo.co/read/2078805/super-flu-virus-is-weak-variant-says-health-minister","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/2078805/super-flu-virus-is-weak-variant-says-health-minister","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["WGS","BK4196"],"gpt_icon":0},{"id":"2601672890","title":"GeneDx Appoints Dr. Linda Genen as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2601672890","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601672890?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:30","pubTimestamp":1767706246,"startTime":"0","endTime":"0","summary":"GeneDx Holdings Corp. has appointed Dr. Linda Genen, MD, MPH as Chief Medical Officer. Dr. Genen will lead the company's medical and clinical affairs, shape clinical strategy, and work to expand the adoption of genomic medicine in healthcare. She joins GeneDx from ProgenyHealth, where she previously served as Chief Medical Officer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genedx Holdings Corp. published the original content used to generate this news brief via Business Wire  on January 06, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL9x0mSr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WGS","BK4196"],"gpt_icon":0},{"id":"2601555890","title":"GeneDx Appoints DR. Linda Genen as Chief Medical Officer to Accelerate the Future of Genomic-First Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2601555890","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601555890?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:30","pubTimestamp":1767706203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nTUA6MF9LP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4196","WGS"],"gpt_icon":0},{"id":"2601809884","title":"GeneDx Achieves Record Research Milestones with Landmark Rare Disease Genomics Studies in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2601809884","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601809884?lang=en_us&edition=fundamental","pubTime":"2026-01-05 21:30","pubTimestamp":1767619850,"startTime":"0","endTime":"0","summary":"GeneDx Holdings Corp. announced a record-setting year in 2025 for its Medical Affairs and research programs, publishing 79 peer-reviewed studies and surpassing a total of 1,100 publications related to rare disease genomics. Among the most notable was the GUARDIAN  study, which received recognition in JAMA's annual Research of the Year Roundup for its findings on the effectiveness of genomic newborn screening in identifying serious, actionable childhood conditions beyond traditional methods. In addition, GeneDx advanced genome-first clinical care with publications such as SeqFirst Neo, supporting rapid genome sequencing for critically ill newborns, and SeqFirst Floor, demonstrating first-tier rapid genome sequencing in non-critical pediatric wards. These results have already been published. The company also reported contributions to 56 GeneMatcher publications in 2025, facilitating global collaboration and resulting in 31 newly clinically validated gene-disease associations.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDLc7y1Qj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","WGS"],"gpt_icon":0},{"id":"2593809774","title":"GeneDx Holdings Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2593809774","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593809774?lang=en_us&edition=fundamental","pubTime":"2025-12-22 21:14","pubTimestamp":1766409240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/WGS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 22, 2025 08:14 ET (13:14 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WGS"],"gpt_icon":0},{"id":"2592964491","title":"GeneDx Holdings Corp : Jefferies Raises Target Price to $180 From $150","url":"https://stock-news.laohu8.com/highlight/detail?id=2592964491","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592964491?lang=en_us&edition=fundamental","pubTime":"2025-12-17 15:25","pubTimestamp":1765956301,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nFWN3XN0E3:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["WGS","BK4196"],"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.genedx.com","stockEarnings":[{"period":"1week","weight":-0.2343},{"period":"1month","weight":-0.3058},{"period":"3month","weight":-0.117},{"period":"6month","weight":0.3428},{"period":"1year","weight":0.4521},{"period":"ytd","weight":-0.1961}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0141},{"period":"3month","weight":0.045},{"period":"6month","weight":0.1},{"period":"1year","weight":0.1858},{"period":"ytd","weight":0.0124}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It also provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. is headquartered in Stamford, Connecticut.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.114678},{"month":2,"riseRate":1,"avgChangeRate":0.457595},{"month":3,"riseRate":0.2,"avgChangeRate":-0.132973},{"month":4,"riseRate":0.2,"avgChangeRate":-0.003121},{"month":5,"riseRate":0.4,"avgChangeRate":-0.013957},{"month":6,"riseRate":0.6,"avgChangeRate":0.029191},{"month":7,"riseRate":0.8,"avgChangeRate":0.138059},{"month":8,"riseRate":0.2,"avgChangeRate":-0.136267},{"month":9,"riseRate":0.2,"avgChangeRate":-0.072401},{"month":10,"riseRate":0.8,"avgChangeRate":0.18872},{"month":11,"riseRate":0.2,"avgChangeRate":-0.130294},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.04765}],"exchange":"NASDAQ","name":"GeneDx Holdings","nameEN":"GeneDx Holdings"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"GeneDx Holdings(WGS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest GeneDx Holdings(WGS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"GeneDx Holdings,WGS,GeneDx Holdings股票,GeneDx Holdings股票老虎,GeneDx Holdings股票老虎国际,GeneDx Holdings行情,GeneDx Holdings股票行情,GeneDx Holdings股价,GeneDx Holdings股市,GeneDx Holdings股票价格,GeneDx Holdings股票交易,GeneDx Holdings股票购买,GeneDx Holdings股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"GeneDx Holdings(WGS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest GeneDx Holdings(WGS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction